PMID- 33678047
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
VI  - 72
IP  - 8
DP  - 2021 Sep
TI  - The Effect of Platelet-Rich Plasma on Endothelial Progenitor Cell Functionality.
PG  - 776-786
LID - 10.1177/0003319721998895 [doi]
AB  - Platelets mediate circulating endothelial progenitor cell (EPC) recruitment and 
      maturation, participating in vascular repair, however the underlying mechanism(s) 
      remain unclear. We investigated the effect of platelet-rich plasma (PRP) on the 
      functionality of CD34(+)-derived late-outgrowth endothelial cells (OECs) in 
      culture. Confluent OECs were coincubated with PRP under platelet aggregation 
      (with adenosine diphosphate; ADP) and nonaggregation conditions, in the 
      presence/absence of the reversible P2Y12 platelet receptor antagonist ticagrelor. 
      Outgrowth endothelial cell activation was evaluated by determining prostacyclin 
      (PGI(2)) and monocyte chemoattractant protein-1 (MCP-1) release and intercellular 
      adhesion molecule-1 (ICAM-1) membrane expression. Similar experiments were 
      performed using human umbilical vein endothelial cells (HUVECs). Platelet-rich 
      plasma increased ICAM-1 expression and PGI(2) and MCP-1 secretion compared with 
      autologous platelet-poor plasma, whereas ADP-aggregated platelets in PRP did not 
      exhibit any effect. Platelet-rich plasma pretreated with ticagrelor prior to 
      activation with ADP increased all markers to a similar extent as PRP. Similar 
      results were obtained using HUVECs. In conclusion, PRP induces OEC activation, a 
      phenomenon not observed when platelets are aggregated with ADP. Platelet 
      inhibition with ticagrelor restores the PRP capability to activate OECs. Since 
      EPC activation is important for endothelial regeneration and angiogenesis, we 
      suggest that agents inhibiting platelet aggregation, such as ticagrelor, may 
      promote platelet-EPC interaction and EPC function.
FAU - Sidiropoulou, Sofia
AU  - Sidiropoulou S
AUID- ORCID: 0000-0001-8077-7087
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
FAU - Papadaki, Styliani
AU  - Papadaki S
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
FAU - Tsouka, Aikaterini N
AU  - Tsouka AN
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
FAU - Koutsaliaris, Ioannis K
AU  - Koutsaliaris IK
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
FAU - Chantzichristos, Vasileios G
AU  - Chantzichristos VG
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
FAU - Pantazi, Despoina
AU  - Pantazi D
AUID- ORCID: 0000-0001-6636-5959
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
FAU - Paschopoulos, Minas E
AU  - Paschopoulos ME
AD  - Department of Obstetrics and Gynecology, School of Medicine, University of 
      Ioannina, Ioannina, Greece.
FAU - Hansson, Kenny M
AU  - Hansson KM
AUID- ORCID: 0000-0003-0448-5140
AD  - Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal 
      and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
FAU - Tselepis, Alexandros D
AU  - Tselepis AD
AUID- ORCID: 0000-0002-5854-2385
AD  - Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of 
      Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
LA  - eng
PT  - Journal Article
DEP - 20210308
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Antigens, CD34)
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (ICAM1 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - GLH0314RVC (Ticagrelor)
SB  - IM
MH  - Antigens, CD34/metabolism
MH  - Biomarkers/metabolism
MH  - Blood Platelets/drug effects/*metabolism
MH  - *Cell Communication/drug effects
MH  - Cells, Cultured
MH  - Chemokine CCL2/metabolism
MH  - Endothelial Progenitor Cells/drug effects/*metabolism
MH  - Epoprostenol/metabolism
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet-Rich Plasma/drug effects/*metabolism
MH  - Ticagrelor/pharmacology
OTO - NOTNLM
OT  - endothelial cell activation markers
OT  - endothelial progenitor cells
OT  - human umbilical vein endothelial cells
OT  - platelet-rich plasma
OT  - ticagrelor
EDAT- 2021/03/09 06:00
MHDA- 2021/08/31 06:00
CRDT- 2021/03/08 05:29
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2021/03/08 05:29 [entrez]
AID - 10.1177/0003319721998895 [doi]
PST - ppublish
SO  - Angiology. 2021 Sep;72(8):776-786. doi: 10.1177/0003319721998895. Epub 2021 Mar 
      8.